• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    118.31 +1.24 (+1.06%)
    Streaming Delayed Price Updated: 1:43 PM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mirum Pharmaceuticals, Inc. - common stock

    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 Next >
    News headline image
    'It Is Too Sizzling For Me': Why Jim Cramer Isn't Buying This 'Red Hot' Group Of Stocks ↗
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. (NASDAQ: KELYA) is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them.... 
    Via Benzinga
    News headline image
    Looking Into Mirum Pharmaceuticals's Return On Capital Employed ↗
    According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ:MIRM) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceuticals still reported an overall loss of... 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Recap: Mirum Pharmaceuticals Q2 Earnings ↗
    Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    News headline image
    Expert Ratings for Mirum Pharmaceuticals ↗
    Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: 
    Via Benzinga
    News headline image
    Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered ↗
    Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share.... 
    Via Benzinga
    News headline image
    Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharma Acquires Its Licensing Partner In Cash and Stock ↗
     
    Via Benzinga
    News headline image
    Recap: Mirum Pharmaceuticals Q1 Earnings ↗
    Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Gainers 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    A Preview Of Mirum Pharmaceuticals's Earnings ↗
    Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Mirum... 
    Via Benzinga
    News headline image
    83 Biggest Movers From Yesterday ↗
    Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
    Via Benzinga
    News headline image
    57 Stocks Moving In Thursday's Mid-Day Session ↗
    Gainers 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.